Literature DB >> 29506418

HCV in Egypt, prevention, treatment and key barriers to elimination.

Mohamed El Kassas1, Tamer Elbaz2, Aisha Elsharkawy2, Heba Omar2, Gamal Esmat2.   

Abstract

INTRODUCTION: Currently, direct-acting antivirals (DAAs) are considered the ideal choice for the treatment of chronic HCV patients due to their proven efficacy (SVR> 90%), and minimal adverse effects. Egypt launched a large treatment program aimed at providing treatment coverage for Egyptian HCV- infected patients. Areas covered: This review covers the treatment and prevention efforts made by the Egyptian National Committee for the Control of Viral Hepatitis (NCCVH) with the available model of care for HCV patients in Egypt, in addition to the barriers that prevent elimination of HCV from Egypt. Expert commentary: Egypt could provide a model for establishing the largest HCV management system aimed at eliminating HCV from the country with the highest worldwide prevalence. Despite the huge efforts and achieved results in combating the HCV epidemic in Egypt, certain improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.

Entities:  

Keywords:  Egypt; HCV; elimination; prevention; treatment

Mesh:

Substances:

Year:  2018        PMID: 29506418     DOI: 10.1080/14787210.2018.1448709

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  11 in total

Review 1.  Hepatitis C elimination: a Public Health Perspective.

Authors:  Radha K Dhiman; Gagandeep S Grover; Madhumita Premkumar
Journal:  Curr Treat Options Gastroenterol       Date:  2019-09

2.  Liver Disease Outcomes after Sustained Virological Response in Patients with Chronic Hepatitis C Infection Treated with Generic Direct-Acting Antivirals.

Authors:  Ekram W Abd El-Wahab; Waleed M Abd Elgawad; Mohamed S Abdelaziz; Ashraf I Mikheal; Hanan Z Shatat
Journal:  Am J Trop Med Hyg       Date:  2022-02-28       Impact factor: 3.707

3.  Mass screening for hepatitis B and C in Southern Upper Egypt.

Authors:  Gamal Soliman; Mahmoud S Elzalabany; Tarek Hassanein; F DeWolfe Miller
Journal:  BMC Public Health       Date:  2019-10-22       Impact factor: 3.295

4.  Letter regarding "High rates of 30-day mortality in patients with cirrhosis and COVID-19".

Authors:  Mohammed A Medhat; Mohamed El Kassas
Journal:  J Hepatol       Date:  2020-06-20       Impact factor: 25.083

5.  Eliminating hepatitis C from countries with high prevalence: When infrastructure comes first.

Authors:  Gamal Esmat; Mohamed El Kassas
Journal:  Indian J Med Res       Date:  2021-07       Impact factor: 2.375

Review 6.  Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures.

Authors:  Reem Ezzat; Mohamed Eltabbakh; Mohamed El Kassas
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

7.  Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Amany Mohamed Salah Eldin Wahb; Mohamed El Kassas; Ahmed Kamal Khamis; Mostafa Elhelbawy; Nesreen Elhelbawy; Mona Salah Eldin Habieb
Journal:  World J Hepatol       Date:  2021-11-27

8.  Pursuing Elimination of Hepatitis C in Egypt: Cost-Effectiveness and Economic Evaluation of a Country-Wide Program.

Authors:  Bjoern Schwander; Josh Feldstein; Suela Sulo; Luis Gonzalez; Galal ElShishiney; Mohamed Hassany
Journal:  Infect Dis Ther       Date:  2022-04-22

9.  COVID-19 in Egypt: Through crisis to adaptation; a gastroenterologist's perspective.

Authors:  Mohamed El Kassas; Haytham Abdelkader; Mohammed A Medhat
Journal:  Arab J Gastroenterol       Date:  2020-07-19       Impact factor: 2.076

10.  Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations.

Authors:  Mohamed El Kassas; Osama Mo Hegazy; Eman M Salah
Journal:  World J Hepatol       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.